Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that omarigliptin, Merck’s investigational once-weekly
DPP-4 inhibitor in development for adults with type 2 diabetes, achieved
its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found
to be non-inferior to Merck’s once-daily DPP-4 inhibitor, JANUVIA®
(sitagliptin), at reducing patients’ A1C* levels
from baseline, with similar A1C reductions achieved in both groups.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Janumet | Januvia | Merck | Metformin | Pharmaceuticals | Study